Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients
Launched by NAHLA H TOHAMI · Jun 27, 2018
Trial Information
Current as of June 28, 2025
Unknown status
Keywords
ClinConnect Summary
Diabetic nephropathy involves progressive stages including glomerular hyperfilteration , microalbuminuria , overt proteinuria and a decline in glomerular filteration rate leading to end stage renal disease.
Despite all the available interventions available for diabetic patients including tight glycemic control , and blood pressure control , using angiotensin converting enzyme inhibitors, angiotensin II receptor antagonist renal disease remains prevalent and progress in these patients.
The newer therapy of diabetes is the use of sodium glucose cotransporter 2 inhibitor as it has the potent...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients with type 2 diabetes.
- • controlled diabetes.
- • patients with proteinuria
- Exclusion Criteria:
- • patients with proteinuria due to other disease.
- • patients with HbA1c \>8%.
- • patients with uncontrolled hypertension.
- • patients with chronic liver disease.
- • patients with type 1 diabetes .
- • patients already on the same drug ( dapagliflozine).
- • patients with raised serum creatinine.
About Nahla H Tohami
Nahla H. Tohami is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient care through innovative studies. With a focus on ethical standards and regulatory compliance, Tohami leads initiatives that explore novel therapeutic interventions across various therapeutic areas. Her organization emphasizes collaboration with healthcare professionals and research institutions to ensure robust study designs and reliable outcomes. Through rigorous methodologies and a patient-centric approach, Nahla H. Tohami aims to contribute significantly to the growing body of clinical knowledge and improve treatment options for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Trial Officials
Magdy Sharkawy, MD
Study Director
Ain Shams University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials